新发与复发性巨细胞动脉炎接受托珠单抗治疗:随机对照试验及延伸研究的3年结果
该分析基于GiACTA试验第1部分(双盲52周)及第2部分(开放标签104周),按原始治疗分组评估新发与复发性巨细胞动脉炎患者3年内首次复发时间及累积糖皮质激素暴露。每周托珠单抗组新发与复发患者的中位首次复发时间分别为577天和575天,均长于每两周方案及安慰剂组,累积激素剂量也更低。作者认为数据支持将每周托珠单抗作为所有活动性巨细胞动脉炎患者一线治疗的一部分。
要点
- 每周托珠单抗组新发与复发患者中位首次复发时间分别为577天和575天,安慰剂组为179天和224天。
- 每周托珠单抗组新发与复发患者中位累积激素剂量分别为3068 mg和2191 mg,低于每两周方案及安慰剂组。
- 作者认为数据支持将每周托珠单抗作为所有活动性巨细胞动脉炎患者一线治疗的一部分。
核心结论
- 每周托珠单抗延迟了新发和复发性巨细胞动脉炎患者的复发时间,并降低了累积糖皮质激素剂量。
- 作者认为这些数据支持将每周托珠单抗作为所有活动性巨细胞动脉炎患者一线治疗的一部分。
研究设计与样本
- GiACTA第1部分为双盲随机对照试验,患者接受每周托珠单抗、每两周托珠单抗或安慰剂治疗52周,并联合泼尼松减量方案。
- 第2部分为开放标签延伸研究,由研究者酌情治疗104周。
- 本分析按患者原始治疗分组评估52周后的结局。
- 第1部分入组250例患者,其中215例进入第2部分。
主要发现
- 基线时48%为新发疾病,52%为复发性疾病。
- 新发与复发患者中,每周托珠单抗组中位首次复发时间分别为577天和575天,每两周托珠单抗组分别为479天和428天,安慰剂组分别为179天和224天。
- 新发与复发患者中,每周托珠单抗组中位累积糖皮质激素剂量分别为3068 mg和2191 mg,每两周托珠单抗组分别为4080 mg和2353 mg,安慰剂组分别为4639 mg和6178 mg。
关键数值与推荐
- 新发患者每周托珠单抗组中位首次复发时间577天 vs 每两周组479天 vs 安慰剂组179天。
- 复发患者每周托珠单抗组中位首次复发时间575天 vs 每两周组428天 vs 安慰剂组224天。
- 新发患者每周托珠单抗组中位累积激素剂量3068 mg vs 每两周组4080 mg vs 安慰剂组4639 mg。
- 复发患者每周托珠单抗组中位累积激素剂量2191 mg vs 每两周组2353 mg vs 安慰剂组6178 mg。
临床怎么用
- 作者认为数据支持将每周托珠单抗作为所有活动性巨细胞动脉炎患者一线治疗的一部分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tocilizumab plus prednisone induces sustained glucocorticoid-free remission in patients with GCA. However, its long-term benefits in new-onset vs relapsing disease are uncertain, and the value of weekly vs every-other-week dosing has not been evaluated. METHODS: In Giant-Cell Arteritis Actemra (GiACTA) part 1, patients with new-onset or relapsing GCA received blinded tocilizumab weekly (TCZ QW), tocilizumab every-other-week (TCZ Q2W) or placebo for 52 weeks, with a prednisone taper. In part 2 (open-label), patients were treated at investigator discretion for 104 weeks. In this analysis, patients were evaluated according to their original treatment assignments, and outcomes beyond 52 weeks were assessed. Outcomes of interest included time to first flare and cumulative glucocorticoid exposure over 3 years according to baseline disease status. RESULTS: Part 1 enrolled 250 patients; 215 entered part 2. At baseline, 48% had new-onset disease and 52% had relapsing disease. In patients with new-onset and relapsing disease, the median time to first flare in the TCZ QW group was 577 and 575 days, respectively, vs 479 and 428 days with TCZ Q2W and 179 and 224 days with placebo; the median cumulative glucocorticoid dose was 3068 mg and 2191 mg with TCZ QW, 4080 mg and 2353 mg with TCZ Q2W, and 4639 mg and 6178 mg with placebo. CONCLUSION: TCZ QW delayed the time to flare and reduced the cumulative glucocorticoid dose in patients with relapsing GCA and new-onset GCA. These data support initiating TCZ QW as part of first-line therapy in all patients with active GCA. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT01791153.
引用
- Stone JH, Spotswood H, Unizony SH, et al. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology (Oxford). 2022. PMID: 34718434. doi:10.1093/rheumatology/keab780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。